[Effectiveness of the local use of komplamin and ATP in treating patients with primary and secondary optic atrophy].
D000255:Adenosine Triphosphate / Q000627:therapeutic use*; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D008875:Middle Aged; D009216:Myopia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D009896:Optic Atrophy / Q000188:drug therapy* / Q000503:physiopathology; D012162:Retinal Degeneration / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D013806:Theophylline / Q000031:analogs & derivatives*; D014792:Visual Acuity / Q000187:drug effects; D014971:Xanthinol Niacinate / Q000627:therapeutic use*
D014971:Xanthinol Niacinate; D000255:Adenosine Triphosphate; D013806:Theophylline
Effektivnost' mestnogo primeneniia komplamina i ATF pri lechenii bol'nykh s pervichnoĭ i vtorichnoĭ atrofieĭ zritel'nogo nerva.